



**ASX & MEDIA RELEASE
22 MARCH, 2010**

**MARSHALL EDWARDS ANNOUNCES PUBLICATION OF PHASE II CLINICAL TRIAL RESULTS
HIGHLIGHTING ACTIVITY OF INTRAVENOUS PHENOXODIOL**

Novogen Limited's subsidiary, Marshall Edwards, Inc., (NASDAQ: MSHL) has made the following announcement.

Study suggests phenoxodiol is active when administered intravenously in combination with platinum-based chemotherapy for ovarian cancer

San Diego – 21 March, 2011– Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from a Phase II clinical trial of intravenous phenoxodiol in combination with cisplatin in women with platinum-resistant ovarian cancer. The publication is now available on the *International Journal of Gynecological Cancer* website and scheduled to print in the May issue of the journal.

The study, conducted at Yale-New Haven Hospital, showed that the combination of intravenous phenoxodiol, a novel NADH oxidase inhibitor, with cisplatin, a platinum-based chemotherapy, was well tolerated and resulted in an overall response rate of 19% (3 out of 16) among ovarian cancer patients previously resistant to platinum. Response rate in this study was defined as the percentage of patients whose tumour demonstrated a radiologically confirmed reduction or disappearance after treatment. An abstract can be found at www.marshalledwardsinc.com/our-programs/scientific-publications that describes more information on the trial results.

“These results suggest that the combination of intravenous phenoxodiol with cisplatin has a good safety profile and may be capable of reversing resistance to platinum-based chemotherapy,” said lead author Michael G Kelly, MD, a gynecologic oncologist at Tufts Medical Center and former fellow at Yale University School of Medicine. “This study provides early clinical proof-of-concept for the combination of NADH oxidase inhibitors with standard-of-care chemotherapy and lays the groundwork for the development of more potent next-generation compounds.”

To date, phenoxodiol, an investigational drug, has been introduced into more than 400 patients in multiple clinical trials via oral or intravenous routes and has been well tolerated. Marshall Edwards has identified a next-generation compound called NV-143 that in laboratory studies has demonstrated significantly more activity than phenoxodiol against a broad range of tumour cell lines. In addition to being more active as a single agent, NV-143 appears to be superior in its ability to synergise with platinum-based chemotherapy in pre-clinical studies. As a result, the Company plans to initiate a Phase I clinical trial of intravenous NV-143 later this year, followed immediately thereafter by randomized Phase II trials in combination with chemotherapy.

“These published results combined with data from previous studies reinforce our conclusion that intravenous administration is the optimal route of delivery for this class of drugs and give us added

confidence moving forward as we develop our next-generation compound NV-143 for the clinic,” said Robert D Mass, MD, Acting Chief Medical Officer of Marshall Edwards.

About Marshall Edwards

Marshall Edwards, Inc. is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company’s lead programs focus on two families of small molecules that result in the inhibition of tumour cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes lead drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.

About Novogen Limited

Novogen Limited (ASX: NRT Nasdaq: NVGN) is an Australian biotechnology company based in Sydney, Australia. Novogen has a consumer healthcare business, conducts research and development on oncology therapeutics through its 71.3 per cent owned subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its 80.7 per cent owned subsidiary, Glycotex, Inc. More information on the Novogen group of companies can be found at www.novogen.com.

ISSUED FOR	:	NOVOGEN LIMITED
LISTINGS	:	ASX (CODE NRT), NASDAQ (CODE NVGN).
FOR FURTHER INFORMATION :	:	PETE DE SPAIN, SR DIRECTOR IR AND CORPORATE COMMUNICATIONS, MARSHALL EDWARDS, INC. TEL +1 858-792-3729 http://www.marshalledwardsinc.com
ISSUED BY CONTACT	:	WESTBROOK COMMUNICATIONS IAN WESTBROOK TEL (02) 9231 0922